{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:32:04Z","timestamp":1790260324118,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T00:00:00Z","timestamp":1689552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:p>Alport syndrome (#308940) is an X-linked genetic disease with clinical manifestations, such as hematuria, proteinuria, renal insufficiency, and end-stage renal disease. The disease is characterized by the thinning of the glomerular basement membrane in the early stages and the thickening of the glomerular basement membrane in the late stages and may be associated with ocular lesions and varying degrees of sensorineural deafness. Herein, we report a case of Alport syndrome caused by a <jats:italic>de novo<\/jats:italic> mutation in <jats:italic>COL4A5<\/jats:italic>. The patient was a young male with clinical manifestations of hematuria and massive proteinuria who was diagnosed with Alport syndrome based on renal pathology and genetic testing.<\/jats:p>","DOI":"10.3389\/fgene.2023.1216809","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T19:40:14Z","timestamp":1689622814000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case report: A case report of Alport syndrome caused by a novel mutation of COL4A5"],"prefix":"10.3389","volume":"14","author":[{"given":"Shujun","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizhen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,7,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/ckj\/sft144","article-title":"Genetic testing can resolve diagnostic confusion in Alport syndrome","volume":"7","author":"Adam","year":"2014","journal-title":"Clin. Kidney J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1136\/bmj.1.3454.504","article-title":"HereditaryE familial congenital haemorrhagic nephritis","volume":"1","author":"Alport","year":"1927","journal-title":"Br. Med. J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ekir.2021.10.012","article-title":"Last nucleotide substitutions of COL4A5 exons cause aberrant splicing","volume":"7","author":"Aoto","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2009070784","article-title":"Genotype-phenotype correlation in X-linked Alport syndrome","volume":"21","author":"Bekheirnia","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1093\/ndt\/gfac006","article-title":"Lifelong effect of therapy in young patients with the COL4A5 Alport missense variant p (Gly624Asp): A prospective cohort study","volume":"37","author":"Boeckhaus","year":"2022","journal-title":"Nephrol. Dial. Transpl."},{"key":"B6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/ki.2015.317","article-title":"Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhood-onset increased renal echogenicity","volume":"89","author":"Braun","year":"2016","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.matbio.2016.08.005","article-title":"Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome","author":"Cosgrove","year":"2017","journal-title":"Matrix Biol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/cge.12258","article-title":"Unbiased next generation sequencing analysis confirms the existence of autosomal dominant Alport syndrome in a relevant fraction of cases","volume":"86","author":"Fallerini","year":"2014","journal-title":"Clin. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/cge.12919","article-title":"Alport syndrome: Impact of digenic inheritance in patients management","volume":"92","author":"Fallerini","year":"2017","journal-title":"Clin. Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1053\/j.ajkd.2021.02.326","article-title":"Clinical and genetic features of autosomal dominant Alport syndrome: A cohort study","volume":"78","author":"Furlano","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1681\/ASN.2018030228","article-title":"Detection of splicing abnormalities and genotype-phenotype correlation in X-linked Alport syndrome","volume":"29","author":"Horinouchi","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2215\/CJN.01000116","article-title":"Genetic, clinical, and pathologic backgrounds of patients with autosomal dominant Alport syndrome","volume":"11","author":"Kamiyoshi","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport syndrome: Achieving early diagnosis and treatment","volume":"77","author":"Kashtan","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrneph.2012.259","article-title":"Alport syndrome--insights from basic and clinical research","volume":"9","author":"Kruegel","year":"2013","journal-title":"Nat. Rev. Nephrol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1042\/CS20191276","article-title":"SGLT2 inhibitors - a potential treatment for Alport syndrome","volume":"134","author":"Mabillard","year":"2020","journal-title":"Clin. Sci. (Lond)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.kint.2017.06.013","article-title":"Massively parallel sequencing and targeted exomes in familial kidney disease can diagnose underlying genetic disorders","volume":"92","author":"Mallett","year":"2017","journal-title":"Kidney Int."},{"key":"B18","doi-asserted-by":"publisher","first-page":"580376","DOI":"10.3389\/fmed.2020.580376","article-title":"X-linked Alport syndrome in women: Genotype and clinical course in 24 cases","volume":"7","author":"Mastrangelo","year":"2020","journal-title":"Front. Med. (Lausanne)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.kint.2018.06.031","article-title":"Hydroxypropyl-\u03b2-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis","volume":"94","author":"Mitrofanova","year":"2018","journal-title":"Kidney Int."},{"key":"B20","doi-asserted-by":"publisher","first-page":"7053","DOI":"10.1038\/s41598-021-86109-1","article-title":"Metformin ameliorates the severity of experimental Alport syndrome","volume":"11","author":"Omachi","year":"2021","journal-title":"Sci. Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/nejmoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"5995","DOI":"10.1093\/nar\/gkm647","article-title":"In vitro and in silico analysis reveals an efficient algorithm to predict the splicing consequences of mutations at the 5' splice sites","volume":"35","author":"Sahashi","year":"2007","journal-title":"Nucleic Acids Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1053\/j.ajkd.2021.04.017","article-title":"Pathogenic variants in the genes affected in Alport syndrome (COL4A3-COL4A5) and their association with other kidney Conditions: A review","volume":"78","author":"Savige","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2215\/CJN.10581014","article-title":"Ocular features in Alport syndrome: Pathogenesis and clinical significance","volume":"10","author":"Savige","year":"2015","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1681\/ASN.2020060777","article-title":"Uncovering modifier genes of X-linked Alport syndrome using a novel multiparent mouse model","volume":"32","author":"Takemon","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1086\/302418","article-title":"Splicing defects in the ataxia-telangiectasia gene, ATM: Underlying mutations and consequences","volume":"64","author":"Teraoka","year":"1999","journal-title":"Am. J. Hum. Genet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41581-021-00451-1","article-title":"Complex genetics of Alport and Goodpasture syndromes","volume":"17","author":"Tryggvason","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00467-013-2643-0","article-title":"Clinical and genetic features in autosomal recessive and X-linked Alport syndrome","volume":"29","author":"Wang","year":"2014","journal-title":"Pediatr. Nephrol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1038\/s41467-021-24890-3","article-title":"Compounds targeting OSBPL7 increase ABCA1-dependent cholesterol efflux preserving kidney function in two models of kidney disease","volume":"12","author":"Wright","year":"2021","journal-title":"Nat. Commun."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1038\/s41467-020-16605-x","article-title":"Development of an exon skipping therapy for X-linked Alport syndrome with truncating variants in COL4A5","volume":"11","author":"Yamamura","year":"","journal-title":"Nat. Commun."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype-phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"","journal-title":"Kidney Int."},{"key":"B33","doi-asserted-by":"publisher","first-page":"119857","DOI":"10.1016\/j.biomaterials.2020.119857","article-title":"Adverse effects of Alport syndrome-related Gly missense mutations on collagen type IV: Insights from molecular simulations and experiments","volume":"240","author":"Yeo","year":"2020","journal-title":"Biomaterials"},{"key":"B34","doi-asserted-by":"publisher","first-page":"gfad105","DOI":"10.1093\/ndt\/gfad105","article-title":"Effectiveness of reninangiotensin-aldosterone system blockers in patients with Alport syndrome: A systematic review and meta-analysis","author":"Zeng","year":"","journal-title":"Nephrol. Dial. Transpl."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s00467-021-05040-9","article-title":"Genotype-phenotype correlations and nephroprotective effects of RAAS inhibition in patients with autosomal recessive Alport syndrome","volume":"36","author":"Zhang","year":"2021","journal-title":"Pediatr. Nephrol."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2023.1216809\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T19:40:16Z","timestamp":1689622816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2023.1216809\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,17]]},"references-count":35,"alternative-id":["10.3389\/fgene.2023.1216809"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2023.1216809","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,17]]},"article-number":"1216809"}}